title: [Targeted therapies in digestive oncology].
abstract: Targeted therapies have an increasing importance in digestive oncology. These new treatments have been authorized in colon cancer, gastric cancer, pancreatic cancer, endocrine cancer and gastrointestinal stromal tumors. The oncologist should develop high abilities to use these therapies especially concerning the indications, response's biomarkers, toxicities and evaluation methods.
authors: Service d'oncologie médicale, institut national d'oncologie, CHU Ibn Sina, Rabat, Maroc. boutayebdr@yahoo.fr
authors: S
authors: S
authors: Boutayeb
authors: Y
authors: Y
authors: Bensouda
authors: Z
authors: Z
authors: Fadoulkhair
authors: K
authors: K
authors: Bakkraoui
authors: M
authors: M
authors: Bachouchi
authors: H
authors: H
authors: Errihani
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use / Q000633:toxicity; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004067:Digestive System Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D058990:Molecular Targeted Therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors